Gago-Dominguez, Manuela
Matabuena, Marcos
Redondo, Carmen M.
Patel, Sandip Pravin http://orcid.org/0000-0002-8387-4840
Carracedo, Angel
Ponte, Sara Miranda
Martínez, María Elena
Castelao, J. Esteban
Article History
Received: 22 July 2019
Accepted: 21 July 2020
First Online: 6 August 2020
Change Date: 20 November 2020
Change Type: Correction
Change Details: An amendment to this paper has been published and can be accessed via a link at the top of the paper.
Competing interests
: Dr. Patel receives scientific advisory income from: AstraZeneca, Bristol-Myers Squibb, Illumina, Nektar, Tempus. Dr. Patel’s university receives research funding from: Bristol-Myers Squibb, Eli Lilly, Fate, Incyte, AstraZeneca/MedImmune, Merck, Pfizer, Roche/Genentech, Xcovery. Fate Therapeutics, Genocea, Iovance.